Functional role of P2X7 purinergic receptor in cancer and cancer-related pain.
Antagonists
Cancer pain
P2X7 receptor (P2X7R)
Tumors
Journal
Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499
Informations de publication
Date de publication:
21 May 2024
21 May 2024
Historique:
received:
19
03
2024
accepted:
08
05
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
21
5
2024
Statut:
aheadofprint
Résumé
Numerous studies have revealed that the ATP-gated ion channel purinergic 2X7 receptor (P2X7R) plays an important role in tumor progression and the pathogenesis of cancer pain. P2X7R requires activation by extracellular ATP to perform its regulatory role functions. During tumor development or cancer-induced pain, ATP is released from tumor cells or other cells in the tumor microenvironment (such as tumor-associated immune cells), which activates P2X7R, opens ion channels on the cell membrane, affects intracellular molecular metabolism, and regulates the activity of tumor cells. Furthermore, peripheral organs and receptors can be damaged during tumor progression, and P2X7R expression in nerve cells (such as microglia) is significantly upregulated, enhancing sensory afferent information, sensitizing the central nervous system, and inducing or exacerbating pain. These findings reveal that the ATP-P2X7R signaling axis plays a key regulatory role in the pathogenesis of tumors and cancer pain and also has a therapeutic role. Accordingly, in this study, we explored the role of P2X7R in tumors and cancer pain, discussed the pharmacological properties of inhibiting P2X7R activity (such as the use of antagonists) or blocking its expression in the treatment of tumor and cancer pain, and provided an important evidence for the treatment of both in the future.
Identifiants
pubmed: 38771429
doi: 10.1007/s11302-024-10019-w
pii: 10.1007/s11302-024-10019-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Science and Technology Plan Project of Jiangxi Health Commission
ID : 202310504
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Mair F, Erickson JR, Frutoso M, Konecny AJ, Greene E, Voillet V, Maurice NJ, Rongvaux A, Dixon D, Barber B, Gottardo R, Prlic M (2022) Extricating human tumour immune alterations from tissue inflammation. Nature 605(7911):728–735
pubmed: 35545675
pmcid: 9132772
doi: 10.1038/s41586-022-04718-w
D’Alterio C, Scala S, Sozzi G, Roz L, Bertolini G (2020) Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin Cancer Biol 60:351–361
pubmed: 31454672
doi: 10.1016/j.semcancer.2019.08.019
Lei G, Zhuang L, Gan B (2024) The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell 42(4):513–534
pubmed: 38593779
doi: 10.1016/j.ccell.2024.03.011
Zhang WJ, Luo C, Pu FQ, Zhu JF, Zhu Z (2020) The role and pharmacological characteristics of ATP-gated ionotropic receptor P2X in cancer pain. Pharmacol Res 161:105106
pubmed: 32768625
doi: 10.1016/j.phrs.2020.105106
Ding Z, Liang X, Wang J, Song Z, Guo Q, Schäfer MKE, Huang C (2023) Inhibition of spinal ferroptosis-like cell death alleviates hyperalgesia and spontaneous pain in a mouse model of bone cancer pain. Redox Biol 62:102700
pubmed: 37084690
pmcid: 10141498
doi: 10.1016/j.redox.2023.102700
Ma Y, Han C, Xie C, Dang Q, Yang L, Li Y, Zhang M, Cheng J, Yang Y, Xu Q, Li P (2023) ATP promotes resident CD34+ cell migration mainly through P2Y2-Stim1-ERK/p38 pathway. Am J Physiol Cell Physiol 325(5):C1228–C1243
pubmed: 37721000
doi: 10.1152/ajpcell.00048.2023
Koizumi S, Fujishita K (2007) Gliotransmitter ATP-mediated cell-to-cell communication. Brain Nerve 59(7):707–715
pubmed: 17663141
Zhao GL, Zhou H, Guo YH, Zhong SM, Zhou H, Li F, Lei B, Wang Z, Miao Y (2023) Modulation of Rac1/PAK1/connexin43-mediated ATP release from astrocytes contributes to retinal ganglion cell survival in experimental glaucoma. Glia 71(6):1502–1521
pubmed: 36794533
doi: 10.1002/glia.24354
Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S (2013) Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24(1):130–137
pubmed: 23810565
doi: 10.1016/j.ccr.2013.05.008
Lalo U, Pankratov Y (2023) ATP-mediated signalling in the central synapses. Neuropharmacology 229:109477
pubmed: 36841527
doi: 10.1016/j.neuropharm.2023.109477
Huang KC, Chiang SF, Lin PC, Hong WZ, Yang PC, Chang HP, Peng SL, Chen TW, Ke TW, Liang JA, Chen WT, Chao KSC (2024) TNFα modulates PANX1 activation to promote ATP release and enhance P2RX7-mediated antitumor immune responses after chemotherapy in colorectal cancer. Cell Death Dis 15(1):24
pubmed: 38195677
pmcid: 10776587
doi: 10.1038/s41419-023-06408-5
De Marchi E, Orioli E, Pegoraro A, Adinolfi E, Di Virgilio F (2020) Detection of extracellular ATP in the tumor microenvironment, using the pmeLUC biosensor. Methods Mol Biol 2041:183–195
pubmed: 31646489
doi: 10.1007/978-1-4939-9717-6_13
Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E (2018) Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18(10):601–618
pubmed: 30006588
doi: 10.1038/s41568-018-0037-0
Zou FL, Liu JP, Zuo C, He PF, Ye JX, Zhang WJ (2024) The functional role of P2 purinergic receptors in the progression of gastric cancer. Purinergic Signal. https://doi.org/10.1007/s11302-024-10000-7
Schmid R, Evans RJ (2019) ATP-Gated P2X receptor channels: molecular insights into functional roles. Annu Rev Physiol 81:43–62
pubmed: 30354932
doi: 10.1146/annurev-physiol-020518-114259
Hattori M, Gouaux E (2012) Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 485(7397):207–212
pubmed: 22535247
pmcid: 3391165
doi: 10.1038/nature11010
Smith J, Menéndez Méndez A, Alves M, Parras A, Conte G, Bhattacharya A, Ceusters M, Nicke A, Henshall DC, Jimenez-Mateos EM, Engel T (2023) The P2X7 receptor contributes to seizures and inflammation-driven long-lasting brain hyperexcitability following hypoxia in neonatal mice. Br J Pharmacol 180(13):1710–1729
pubmed: 36637008
doi: 10.1111/bph.16033
Genetzakis E, Gilchrist J, Kassiou M, Figtree GA (2022) Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease? Pharmacol Ther 237:108228
pubmed: 35716953
doi: 10.1016/j.pharmthera.2022.108228
Bernier LP, Ase AR, Séguéla P (2018) P2X receptor channels in chronic pain pathways. Br J Pharmacol 175(12):2219–2230
pubmed: 28728214
doi: 10.1111/bph.13957
Thawkar BS, Kaur G (2019) Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s disease. J Neuroimmunol 326:62–74
pubmed: 30502599
doi: 10.1016/j.jneuroim.2018.11.010
Rabelo ILA, Arnaud-Sampaio VF, Adinolfi E, Ulrich H, Lameu C (2021) Cancer metabostemness and metabolic reprogramming via P2X7 receptor. Cells 10(7):1782
pubmed: 34359950
pmcid: 8305434
doi: 10.3390/cells10071782
Di Virgilio F, Vultaggio-Poma V, Sarti AC (2021) P2X receptors in cancer growth and progression. Biochem Pharmacol 187:114350
pubmed: 33253643
doi: 10.1016/j.bcp.2020.114350
Di Virgilio F, Ferrari D, Adinolfi E (2009) P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal 5(2):251–256
pubmed: 19263244
pmcid: 2686832
doi: 10.1007/s11302-009-9145-3
Franceschini A, Adinolfi E (2014) P2X receptors: New players in cancer pain. World J Biol Chem 5(4):429–436
pubmed: 25426266
pmcid: 4243147
doi: 10.4331/wjbc.v5.i4.429
Chessell I, Hatcher J, Billinton A (2011) Mechanistic differentiation of cancer pain: a pivotal role of P2X7 is absent. Pain 152(8):1703–1704
pubmed: 21514729
doi: 10.1016/j.pain.2011.04.012
Zhang WJ, Zhu ZM, Liu ZX (2020) The role and pharmacological properties of the P2X7 receptor in neuropathic pain. Brain Res Bull 155:19–28
pubmed: 31778766
doi: 10.1016/j.brainresbull.2019.11.006
Ronning KE, Déchelle-Marquet PA, Che Y, Guillonneau X, Sennlaub F, Delarasse C (2023) The P2X7 receptor, a multifaceted receptor in alzheimer’s disease. Int J Mol Sci 24(14):11747
pubmed: 37511507
pmcid: 10380278
doi: 10.3390/ijms241411747
Hu SQ, Hu JL, Zou FL, Liu JP, Luo HL, Hu DX, Wu LD, Zhang WJ (2022) P2X7 receptor in inflammation and pain. Brain Res Bull 187:199–209
pubmed: 35850190
doi: 10.1016/j.brainresbull.2022.07.006
Martínez-Cuesta MÁ, Blanch-Ruiz MA, Ortega-Luna R, Sánchez-López A, Álvarez Á (2020) Structural and functional basis for understanding the biological significance of P2X7 receptor. Int J Mol Sci 21(22):8454
pubmed: 33182829
pmcid: 7696479
doi: 10.3390/ijms21228454
Zuo C, Xu YS, He PF, Zhang WJ (2023) ATP ion channel P2X7 receptor as a regulatory molecule in the progression of colorectal cancer. Eur J Med Chem 261:115877
pubmed: 37857146
doi: 10.1016/j.ejmech.2023.115877
Costa-Junior HM, Sarmento Vieira F, Coutinho-Silva R (2011) C terminus of the P2X7 receptor: treasure hunting. Purinergic Signal 7(1):7–19
pubmed: 21484094
pmcid: 3083127
doi: 10.1007/s11302-011-9215-1
Migita K, Ozaki T, Shimoyama S, Yamada J, Nikaido Y, Furukawa T, Shiba Y, Egan TM, Ueno S (2016) HSP90 regulation of P2X7 receptor function requires an intact cytoplasmic C-Terminus. Mol Pharmacol 90(2):116–126
pubmed: 27301716
pmcid: 11037447
doi: 10.1124/mol.115.102988
Liang X, Samways DSK, Cox J et al (2019) Ca2+ flux through splice variants of the ATP-gated ionotropic receptor P2X7 is regulated by its cytoplasmic N terminus. J Biol Chem 294:12521–12533
pubmed: 31248985
doi: 10.1074/jbc.RA119.009666
Dong Y, Chen Y, Zhang L, Tian Z, Dong S (2020) P2X7 receptor acts as an efficient drug target in regulating bone metabolism system. Biomed Pharmacother 125:110010
pubmed: 32187957
doi: 10.1016/j.biopha.2020.110010
Sperlágh B, Illes P (2014) P2X7 receptor: an emerging target in central nervous system diseases. Trends Pharmacol Sci 35(10):537–547
pubmed: 25223574
doi: 10.1016/j.tips.2014.08.002
Bartlett R, Stokes L, Sluyter R (2014) The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev 66(3):638–675
pubmed: 24928329
doi: 10.1124/pr.113.008003
De Marchi E, Orioli E, Dal Ben D, Adinolfi E (2016) P2X7 Receptor as a therapeutic target. Adv Protein Chem Struct Biol 104:39–79
pubmed: 27038372
doi: 10.1016/bs.apcsb.2015.11.004
Michel AD, Chambers LJ, Walter DS (2008) Negative and positive allosteric modulators of the P2X(7) receptor. Br J Pharmacol 153:737–750
pubmed: 18071294
doi: 10.1038/sj.bjp.0707625
Hattori M, Gouaux E (2012) Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 485:207–212
pubmed: 22535247
pmcid: 3391165
doi: 10.1038/nature11010
Alves LA, Bezerra RJ, Faria RX, Ferreira LG, da Silva FV (2013) Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules 18(9):10953–10972
pubmed: 24013409
pmcid: 6270334
doi: 10.3390/molecules180910953
Wiley JS, Sluyter R, Gu BJ, Stokes L, Fuller SJ (2011) The human P2X7 receptor and its role in innate immunity. Tissue Antigens 78(5):321–332
pubmed: 21988719
doi: 10.1111/j.1399-0039.2011.01780.x
Alarcón-Vila C, Baroja-Mazo A, de Torre-Minguela C, Martínez CM, Martínez-García JJ, Martínez-Banaclocha H, García-Palenciano C, Pelegrin P (2020) CD14 release induced by P2X7 receptor restricts inflammation and increases survival during sepsis. Elife 9:e60849
pubmed: 33135636
pmcid: 7690950
doi: 10.7554/eLife.60849
Rivas-Yáñez E, Barrera-Avalos C, Parra-Tello B, Briceño P, Rosemblatt MV, Saavedra-Almarza J, Rosemblatt M, Acuña-Castillo C, Bono MR, Sauma D (2020) P2X7 receptor at the crossroads of T cell fate. Int J Mol Sci 21(14):4937
pubmed: 32668623
pmcid: 7404255
doi: 10.3390/ijms21144937
Vultaggio-Poma V, Di Virgilio F (2022) P2 receptors: novel disease markers and metabolic checkpoints in immune cells. Biomolecules 12(7):983
pubmed: 35883539
pmcid: 9313346
doi: 10.3390/biom12070983
Francistiová L, Bianchi C, Di Lauro C, Sebastián-Serrano Á, de Diego-García L, Kobolák J, Dinnyés A, Díaz-Hernández M (2020) The role of P2X7 receptor in Alzheimer’s disease. Front Mol Neurosci 13:94
pubmed: 32581707
pmcid: 7283947
doi: 10.3389/fnmol.2020.00094
Kasuya G, Yamaura T, Ma XB, Nakamura R, Takemoto M, Nagumo H, Tanaka E, Dohmae N, Nakane T, Yu Y, Ishitani R, Matsuzaki O, Hattori M, Nureki O (2017) Structural insights into the competitive inhibition of the ATP-gated P2X receptor channel. Nat Commun 8(1):876
pubmed: 29026074
pmcid: 5638823
doi: 10.1038/s41467-017-00887-9
Jindrichová M, Zemková H (2013) Purinergní P2X rodina a specifické vlastnosti P2X7 podtypu [Purinergic P2X family and specific features of the P2X7 subtype]. Cesk Fysiol 62(2):40–46
pubmed: 24392594
Sharma S, Kalra H, Akundi RS (2021) Extracellular ATP mediates cancer cell migration and invasion through increased expression of cyclooxygenase 2. Front Pharmacol 11:617211
pubmed: 33584298
pmcid: 7873692
doi: 10.3389/fphar.2020.617211
Pegoraro A, De Marchi E, Adinolfi E (2021) P2X7 variants in oncogenesis. Cells 10(1):189
pubmed: 33477845
pmcid: 7832898
doi: 10.3390/cells10010189
Burnstock G, Knight GE (2018) The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal 14(1):1–18
pubmed: 29164451
doi: 10.1007/s11302-017-9593-0
Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36(3):293–303
pubmed: 27321181
doi: 10.1038/onc.2016.206
Li Q, Zhu X, Song W, Peng X, Zhao R (2020) The P2X7 purinergic receptor: a potential therapeutic target for lung cancer. J Cancer Res Clin Oncol 146(11):2731–2741
pubmed: 32892231
doi: 10.1007/s00432-020-03379-4
Tang Y, Qiao C, Li Q, Zhu X, Zhao R, Peng X (2023) Research progress in the relationship between P2X7R and cervical cancer. Reprod Sci 30(3):823–834
pubmed: 35799022
doi: 10.1007/s43032-022-01022-w
Bai X, Li Q, Peng X, Li X, Qiao C, Tang Y, Zhao R (2023) P2X7 receptor promotes migration and invasion of non-small cell lung cancer A549 cells through the PI3K/Akt pathways. Purinergic Signal 19(4):685–697
pubmed: 36854856
pmcid: 10754800
doi: 10.1007/s11302-023-09928-z
Roliano GG, Azambuja JH, Brunetto VT, Butterfield HE, Kalil AN, Braganhol E (2022) Colorectal cancer and purinergic signalling: an overview. Cancers (Basel) 14(19):4887
pubmed: 36230810
doi: 10.3390/cancers14194887
Künzli BM, Bernlochner MI, Rath S, Käser S, Csizmadia E, Enjyoji K, Cowan P, d’Apice A, Dwyer K, Rosenberg R, Perren A, Friess H, Maurer CA, Robson SC (2011) Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal 7(2):231–241
pubmed: 21484085
pmcid: 3146639
doi: 10.1007/s11302-011-9228-9
Lili W, Yun L, Tingran W, Xia W, Yanlei S (2019) P2RX7 functions as a putative biomarker of gastric cancer and contributes to worse prognosis. Exp Biol Med (Maywood) 244(9):734–742
pubmed: 31042071
doi: 10.1177/1535370219846492
Zhu X, Li Q, Song W, Peng X, Zhao R (2021) P2X7 receptor: a critical regulator and potential target for breast cancer. J Mol Med (Berl) 99(3):349–358
pubmed: 33486566
doi: 10.1007/s00109-021-02041-x
Magni L, Bouazzi R, Heredero Olmedilla H, Petersen PSS, Tozzi M, Novak I (2021) The P2X7 receptor stimulates IL-6 release from pancreatic stellate cells and tocilizumab prevents activation of STAT3 in pancreatic cancer cells. Cells 10(8):1928
pubmed: 34440697
pmcid: 8391419
doi: 10.3390/cells10081928
Song H, Arredondo Carrera HM, Sprules A, Ji Y, Zhang T, He J, Lawrence E, Gartland A, Luo J, Wang N (2023) C-terminal variants of the P2X7 receptor are associated with prostate cancer progression and bone metastasis - evidence from clinical and pre-clinical data. Cancer Commun (Lond) 43(3):400–404
pubmed: 36582013
doi: 10.1002/cac2.12391
Matyśniak D, Nowak N, Chumak V, Pomorski P (2020) P2X7 receptor activity landscape in rat and human glioma cell lines. Acta Biochim Pol 67(1):7–14
pubmed: 32187491
Benzaquen J, Dit Hreich SJ, Heeke S, Juhel T, Lalvee S, Bauwens S, Saccani S, Lenormand P, Hofman V, Butori M, Leroy S, Berthet JP, Marquette CH, Hofman P, Vouret-Craviari V (2020) P2RX7B is a new theranostic marker for lung adenocarcinoma patients. Theranostics 10(24):10849–10860
pubmed: 33042257
pmcid: 7532666
doi: 10.7150/thno.48229
Calik I, Calik M, Turken G, Ozercan IH (2020) A promising independent prognostic biomarker in colorectal cancer: P2X7 receptor. Int J Clin Exp Pathol 13(2):107–121
pubmed: 32211091
pmcid: 7061807
Qian F, Xiao J, Hu B, Sun N, Yin W, Zhu J (2017) High expression of P2X7R is an independent postoperative indicator of poor prognosis in colorectal cancer. Hum Pathol 64:61–68
pubmed: 28412208
doi: 10.1016/j.humpath.2017.03.019
Zhang Y, Ding J, Wang L (2019) The role of P2X7 receptor in prognosis and metastasis of colorectal cancer. Adv Med Sci 64(2):388–394
pubmed: 31276917
doi: 10.1016/j.advms.2019.05.002
Calik I, Calik M, Sarikaya B, Ozercan IH, Arslan R, Artas G, Dagli AF (2020) P2X7 receptor as an independent prognostic indicator in gastric cancer. Bosn J Basic Med Sci 20(2):188–196
pubmed: 32070268
pmcid: 7202194
Markwardt F (2021) Human P2X7 receptors - Properties of single ATP-gated ion channels. Biochem Pharmacol 187:114307
pubmed: 33130127
doi: 10.1016/j.bcp.2020.114307
Matyśniak D, Chumak V, Nowak N, Kukla A, Lehka L, Oslislok M, Pomorski P (2022) P2X7 receptor: the regulator of glioma tumor development and survival. Purinergic Signal 18(1):135–154
pubmed: 34964926
doi: 10.1007/s11302-021-09834-2
Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 receptor in infection and inflammation. Immunity 47(1):15–31
pubmed: 28723547
doi: 10.1016/j.immuni.2017.06.020
Wu P, Wu X, Zhou G, Wang Y, Liu X, Lv R, Liu Y, Wen Q (2022) P2X7 Receptor-induced bone cancer pain by regulating microglial activity via NLRP3/IL-1beta signaling. Pain Physician 25(8):E1199–E1210
pubmed: 36375190
Stachon P, Heidenreich A, Merz J, Hilgendorf I, Wolf D, Willecke F, von Garlen S, Albrecht P, Härdtner C, Ehrat N, Hoppe N, Reinöhl J, von Zur MC, Bode C, Idzko M, Zirlik A (2017) P2X7 Deficiency blocks lesional inflammasome activity and ameliorates atherosclerosis in mice. Circulation 135(25):2524–2533
pubmed: 28377486
doi: 10.1161/CIRCULATIONAHA.117.027400
Adinolfi E, De Marchi E, Orioli E, Pegoraro A, Di Virgilio F (2019) Role of the P2X7 receptor in tumor-associated inflammation. Curr Opin Pharmacol 47:59–64
pubmed: 30921559
doi: 10.1016/j.coph.2019.02.012
Magnaghi V, Martin S, Smith P, Allen L, Conte V, Reid AJ, Faroni A (2021) Peripheral nerve regeneration following injury is altered in mice lacking P2X7 receptor. Eur J Neurosci 54(5):5798–5814
pubmed: 33012061
doi: 10.1111/ejn.14995
Bravo D, Maturana CJ, Pelissier T, Hernández A, Constandil L (2015) Interactions of pannexin 1 with NMDA and P2X7 receptors in central nervous system pathologies: Possible role on chronic pain. Pharmacol Res 101:86–93
pubmed: 26211949
doi: 10.1016/j.phrs.2015.07.016
Liu C, Tian Q, Wang J, He P, Han S, Guo Y, Yang C, Wang G, Wei H, Li M (2023) Blocking P2RX7 attenuates ferroptosis in endothelium and reduces HG-induced hemorrhagic transformation after MCAO by inhibiting ERK1/2 and P53 signaling pathways. Mol Neurobiol 60(2):460–479
pubmed: 36282438
doi: 10.1007/s12035-022-03092-y
Rossato M, Di Vincenzo A, Pagano C, El Hadi H, Vettor R (2020) The P2X7 receptor and NLRP3 Axis in non-alcoholic fatty liver disease: a brief review. Cells 9(4):1047
pubmed: 32331389
pmcid: 7226571
doi: 10.3390/cells9041047
Caglayan B, Caglayan AB, Beker MC, Yalcin E, Beker M, Kelestemur T, Sertel E, Ozturk G, Kilic U, Sahin F, Kilic E (2017) Evidence that activation of P2X7R does not exacerbate neuronal death after optic nerve transection and focal cerebral ischemia in mice. Exp Neurol 296:23–31
pubmed: 28669743
doi: 10.1016/j.expneurol.2017.06.024
Vázquez-Cuevas FG, Martínez-Ramírez AS, Robles-Martínez L, Garay E, García-Carrancá A, Pérez-Montiel D, Castañeda-García C, Arellano RO (2014) Paracrine stimulation of P2X7 receptor by ATP activates a proliferative pathway in ovarian carcinoma cells. J Cell Biochem 115(11):1955–1966
pubmed: 24913779
Choi JH, Ji YG, Ko JJ, Cho HJ, Lee DH (2018) Activating P2X7 receptors increases proliferation of human pancreatic cancer cells via ERK1/2 and JNK. Pancreas 47(5):643–651
pubmed: 29683976
doi: 10.1097/MPA.0000000000001055
Zhang WJ, Luo C, Huang C, Pu FQ, Zhu JF, Zhu ZM (2021) PI3K/Akt/GSK-3β signal pathway is involved in P2X7 receptor-induced proliferation and EMT of colorectal cancer cells. Eur J Pharmacol 899:174041
pubmed: 33737010
doi: 10.1016/j.ejphar.2021.174041
Yang C, Shi S, Su Y, Tong JS, Li L (2020) P2X7R promotes angiogenesis and tumour-associated macrophage recruitment by regulating the NF-κB signalling pathway in colorectal cancer cells. J Cell Mol Med 24(18):10830–10841
pubmed: 32735377
pmcid: 7521273
doi: 10.1111/jcmm.15708
Ryu JK, Jantaratnotai N, Serrano-Perez MC, McGeer PL, McLarnon JG (2011) Block of purinergic P2X7R inhibits tumor growth in a C6 glioma brain tumor animal model. J Neuropathol Exp Neurol 70(1):13–22
pubmed: 21157381
doi: 10.1097/NEN.0b013e318201d4d4
Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V, Di Virgilio F (2012) Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72(12):2957–2969
pubmed: 22505653
doi: 10.1158/0008-5472.CAN-11-1947
Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, Sarti AC, Bonora M, Syberg S, Corigliano D, Pinton P, Jorgensen NR, Abelli L, Emionite L, Raffaghello L, Pistoia V, Di Virgilio F (2015) Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res 75(4):635–644
pubmed: 25542861
doi: 10.1158/0008-5472.CAN-14-1259
Draganov D, Gopalakrishna-Pillai S, Chen YR, Zuckerman N, Moeller S, Wang C, Ann D, Lee PP (2015) Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Sci Rep 5:16222
pubmed: 26552848
pmcid: 4639773
doi: 10.1038/srep16222
Garg AD, Krysko DV, Vandenabeele P, Agostinis P (2016) Extracellular ATP and P
pubmed: 26890136
pmcid: 5399185
doi: 10.1038/cddis.2015.411
Dreisig K, Sund L, Dommer MW, Kristensen NP, Boddum K, Viste R, Fredholm S, Odum N, Jäättelä M, Skov S, Kornum BR (2018) Human p2y11expression level affects human P2X7 receptor-mediated cell death. Front Immunol 9:1159
pubmed: 29937766
pmcid: 6002484
doi: 10.3389/fimmu.2018.01159
de Andrade MP, Bian S, Savio LEB, Zhang H, Zhang J, Junger W, Wink MR, Lenz G, Buffon A, Wu Y, Robson SC (2017) Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death. Oncotarget 8(40):67254–67268
doi: 10.18632/oncotarget.18595
Bian S, Sun X, Bai A, Zhang C, Li L, Enjyoji K, Junger WG, Robson SC, Wu Y (2013) P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death. PLoS ONE 8(4):e60184
pubmed: 23565201
pmcid: 3615040
doi: 10.1371/journal.pone.0060184
Giannuzzo A, Pedersen SF, Novak I (2015) The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Cancer 14:203
pubmed: 26607222
pmcid: 4660609
doi: 10.1186/s12943-015-0472-4
Avanzato D, Genova T, Fiorio Pla A, Bernardini M, Bianco S, Bussolati B, Mancardi D, Giraudo E, Maione F, Cassoni P, Castellano I, Munaron L (2016) Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and normalizes tumor-derived endothelial cells via cAMP signaling. Sci Rep 6:32602
pubmed: 27586846
pmcid: 5009337
doi: 10.1038/srep32602
Fang J, Chen X, Zhang L, Chen J, Liang Y, Li X, Xiang J, Wang L, Guo G, Zhang B, Zhang W (2013) P2X7R suppression promotes glioma growth through epidermal growth factor receptor signal pathway. Int J Biochem Cell Biol 45(6):1109–1120
pubmed: 23523696
doi: 10.1016/j.biocel.2013.03.005
Zhou Y, Fei M, Zhang G, Liang WC, Lin W, Wu Y, Piskol R, Ridgway J, McNamara E, Huang H, Zhang J, Oh J, Patel JM, Jakubiak D, Lau J, Blackwood B, Bravo DD, Shi Y, Wang J, Hu HM, Lee WP, Jesudason R, Sangaraju D, Modrusan Z, Anderson KR, Warming S, Roose-Girma M, Yan M (2020) Blockade of the phagocytic Receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP. Immunity 52(2):357-373.e9
pubmed: 32049051
doi: 10.1016/j.immuni.2020.01.014
Arnaud-Sampaio VF, Rabelo ILA, Ulrich H, Lameu C (2020) The P2X7 receptor in the maintenance of cancer stem cells, chemoresistance and metastasis. Stem Cell Rev Rep 16(2):288–300
pubmed: 31813120
doi: 10.1007/s12015-019-09936-w
De Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A, Colombo MP, Di Virgilio F, Adinolfi E (2019) The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 38(19):3636–3650
pubmed: 30655604
pmcid: 6756114
doi: 10.1038/s41388-019-0684-y
Qin J, Zhang X, Tan B, Zhang S, Yin C, Xue Q, Zhang Z, Ren H, Chen J, Liu M, Qian M, Du B (2020) Blocking P2X7-mediated macrophage polarization overcomes treatment resistance in lung cancer. Cancer Immunol Res 8(11):1426–1439
pubmed: 32933967
doi: 10.1158/2326-6066.CIR-20-0123
Gehring MP, Kipper F, Nicoletti NF, Sperotto ND, Zanin R, Tamajusuku AS, Flores DG, Meurer L, Roesler R, Filho AB, Lenz G, Campos MM, Morrone FB (2015) P2X7 receptor as predictor gene for glioma radiosensitivity and median survival. Int J Biochem Cell Biol 68:92–100
pubmed: 26358881
doi: 10.1016/j.biocel.2015.09.001
van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JEC, Chang SM (2023) Primary brain tumours in adults. Lancet 402(10412):1564–1579
pubmed: 37738997
doi: 10.1016/S0140-6736(23)01054-1
Lee YT, Tan YJ, Oon CE (2018) Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol 834:188–196
pubmed: 30031797
doi: 10.1016/j.ejphar.2018.07.034
Vessoni AT, Filippi-Chiela EC, Lenz G, Batista LFZ (2020) Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence. Oncogene 39(10):2055–2068
pubmed: 31801972
doi: 10.1038/s41388-019-1128-4
Vultaggio-Poma V, Sarti AC, Di Virgilio F (2020) Extracellular ATP: a feasible target for cancer therapy. Cells 9(11):2496
pubmed: 33212982
pmcid: 7698494
doi: 10.3390/cells9112496
Morrone FB, Gehring MP, Nicoletti NF (2016) Calcium channels and associated receptors in malignant brain tumor therapy. Mol Pharmacol 90(3):403–409
pubmed: 27418672
doi: 10.1124/mol.116.103770
Ren S, Zhang Y, Wang Y, Lui Y, Wei W, Huang X, Mao W, Zuo Y (2010) Targeting P2X
pubmed: 20722629
doi: 10.1042/CBI20090428
Zheng L, Zhang X, Yang F, Zhu J, Zhou P, Yu F, Hou L, Xiao L, He Q, Wang B (2014) Regulation of the P2X7R by microRNA-216b in human breast cancer. Biochem Biophys Res Commun 452(1):197–204
pubmed: 25078617
doi: 10.1016/j.bbrc.2014.07.101
Tsuzuki K, Ase A, Séguéla P et al (2003) TNP-ATP-resistant P2X ionic current on the central terminals and somata of rat primary sensory neurons. J Neurophysiol 89:3235–3242
pubmed: 12783957
doi: 10.1152/jn.01171.2002
Cho JH, Jung KY, Jung Y et al (2013) Design and synthesis of potent and selective P2X
pubmed: 24246730
doi: 10.1016/j.ejmech.2013.10.026
Chen K, Zhang J, Zhang W et al (2013) ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy. Int J Biochem Cell Biol 45:932–943
pubmed: 23434541
doi: 10.1016/j.biocel.2013.02.009
Mousawi F, Peng H, Li J, Ponnambalam S, Roger S, Zhao H, Yang X, Jiang LH (2020) Chemical activation of the Piezo1 channel drives mesenchymal stem cell migration via inducing ATP release and activation of P2 receptor purinergic signaling. Stem Cells 38(3):410–421
pubmed: 31746084
doi: 10.1002/stem.3114
Drill M, Jones NC, Hunn M, O’Brien TJ, Monif M (2021) Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer. Purinergic Signal 17(2):215–227
pubmed: 33728582
pmcid: 8155177
doi: 10.1007/s11302-021-09776-9
Donnelly-Roberts DL, Namovic MT, Surber B, Vaidyanathan SX, Perez-Medrano A, Wang Y, Carroll WA, Jarvis MF (2009) [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology 56(1):223–229
pubmed: 18602931
doi: 10.1016/j.neuropharm.2008.06.012
Santos AA Jr, Cappellari AR, de Marchi FO, Gehring MP, Zaparte A, Brandão CA, Lopes TG, da Silva VD, Pinto LFR, Savio LEB, Moreira-Souza ACA, Coutinho-Silva R, Paccez JD, Zerbini LF, Morrone FB (2017) Potential role of P2X7R in esophageal squamous cell carcinoma proliferation. Purinergic Signal 13(3):279–292
pubmed: 28397110
pmcid: 5563289
doi: 10.1007/s11302-017-9559-2
Kan LK, Drill M, Jayakrishnan PC, Sequeira RP, Galea E, Todaro M, Sanfilippo PG, Hunn M, Williams DA, O’Brien TJ, Drummond KJ, Monif M (2023) P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma. Sci Rep 13(1):8435
pubmed: 37225786
pmcid: 10209214
doi: 10.1038/s41598-023-35712-5
Amoroso F, Capece M, Rotondo A, Cangelosi D, Ferracin M, Franceschini A, Raffaghello L, Pistoia V, Varesio L, Adinolfi E (2015) The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene 34(41):5240–5251
pubmed: 25619831
doi: 10.1038/onc.2014.444
Vázquez-Cuevas FG, Cruz-Rico A, Garay E, García-Carrancá A, Pérez-Montiel D, Juárez B, Arellano RO (2013) Differential expression of the P2X7 receptor in ovarian surface epithelium during the oestrous cycle in the mouse. Reprod Fertil Dev 25(7):971–984
pubmed: 23050672
doi: 10.1071/RD12196
Kan LK, Seneviratne S, Drummond KJ, Williams DA, O’Brien TJ, Monif M (2020) P2X7 receptor antagonism inhibits tumour growth in human high-grade gliomas. Purinergic Signal 16(3):327–336
pubmed: 32583309
pmcid: 7524927
doi: 10.1007/s11302-020-09705-2
Zhang Y, Li F, Wang L, Lou Y (2021) A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2X7 receptor. Biochem Biophys Res Commun 558:147–153
pubmed: 33915328
doi: 10.1016/j.bbrc.2021.04.076
Park JH, Williams DR, Lee JH, Lee SD, Lee JH, Ko H, Lee GE, Kim S, Lee JM, Abdelrahman A, Müller CE, Jung DW, Kim YC (2016) Potent suppressive effects of 1-Piperidinylimidazole based novel P2X7 receptor antagonists on cancer cell migration and invasion. J Med Chem 59(16):7410–7430
pubmed: 27427902
doi: 10.1021/acs.jmedchem.5b01690
Mohammed A, Janakiram NB, Madka V, Pathuri G, Li Q, Ritchie R, Biddick L, Kutche H, Zhang Y, Singh A, Gali H, Lightfoot S, Steele VE, Suen CS, Rao CV (2017) Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. Oncotarget 8(58):97822–97834
pubmed: 29228654
pmcid: 5716694
doi: 10.18632/oncotarget.22085
Sainz B Jr, Alcala S, Garcia E, Sanchez-Ripoll Y, Azevedo MM, Cioffi M, Tatari M, Miranda-Lorenzo I, Hidalgo M, Gomez-Lopez G, Cañamero M, Erkan M, Kleeff J, García-Silva S, Sancho P, Hermann PC, Heeschen C (2015) Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut 64(12):1921–1935
pubmed: 25841238
doi: 10.1136/gutjnl-2014-308935
Ganguly A, Michael M, Goschin S, Harris K, McFarland DC (2022) Cancer pain and opioid use disorder. Oncology (Williston Park) 36(9):535–541
pubmed: 36107782
Ziberi S, Zuccarini M, Carluccio M, Giuliani P, Ricci-Vitiani L, Pallini R, Caciagli F, Di Iorio P, Ciccarelli R (2019) Upregulation of epithelial-to-mesenchymal transition markers and P2X7 receptors is associated to increased invasiveness caused by P2X7 receptor stimulation in human glioblastoma stem cells. Cells 9(1):85
pubmed: 31905754
pmcid: 7016938
doi: 10.3390/cells9010085
Jeddi HM, Busse JW, Sadeghirad B, Levine M, Zoratti MJ, Wang L, Noori A, Couban RJ, Tarride JE (2024) Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials. BMJ Open 14(1):e068182
pubmed: 38171632
pmcid: 10773353
doi: 10.1136/bmjopen-2022-068182
Gehring MP, Pereira TC, Zanin RF, Borges MC, Braga Filho A, Battastini AM, Bogo MR, Lenz G, Campos MM, Morrone FB (2012) P2X7 receptor activation leads to increased cell death in a radiosensitive human glioma cell line. Purinergic Signal 8(4):729–739
pubmed: 22644907
pmcid: 3486168
doi: 10.1007/s11302-012-9319-2
Tanamachi K, Nishino K, Mori N, Suzuki T, Tanuma SI, Abe R, Tsukimoto M (2017) Radiosensitizing Effect of P2X7 receptor antagonist on melanoma in Vitro and in Vivo. Biol Pharm Bull 40(6):878–887
pubmed: 28344198
doi: 10.1248/bpb.b17-00083
Landini L, Marini M, Souza Monteiro de Araujo D, Romitelli A, Montini M, Albanese V, Titiz M, Innocenti A, Bianchini F, Geppetti P, Nassini R, De Logu F (2023) Schwann cell insulin-like growth factor receptor type-1 mediates metastatic bone cancer pain in mice. Brain Behav Immun 110:348–364
pubmed: 36940752
doi: 10.1016/j.bbi.2023.03.013
Wang K, Donnelly CR, Jiang C, Liao Y, Luo X, Tao X, Bang S, McGinnis A, Lee M, Hilton MJ, Ji RR (2021) STING suppresses bone cancer pain via immune and neuronal modulation. Nat Commun 12(1):4558
pubmed: 34315904
pmcid: 8316360
doi: 10.1038/s41467-021-24867-2
Dantigny R, Tanty A, Fourneret P et al (2018) Prevalence of pain in radiotherapy and improvement of its management. Bull Cancer 105:1183–1192
pubmed: 30366592
doi: 10.1016/j.bulcan.2018.08.011
Navia-Pelaez JM, Borgespaes Lemes J, Gonzalez L, Delay L, Dos Santos Aggum Capettini L, Lu JW, Gonçalves Dos Santos G, Gregus AM, Dougherty PM, Yaksh TL, Miller YI (2023) AIBP regulates TRPV1 activation in chemotherapy-induced peripheral neuropathy by controlling lipid raft dynamics and proximity to TLR4 in dorsal root ganglion neurons. Pain 164(6):e274–e285
pubmed: 36719418
doi: 10.1097/j.pain.0000000000002834
Cheatle MD, Falcone M, Dhingra L et al (2020) Independent association of tobacco use with opioid use disorder in patients of European ancestry with chronic non-cancer pain. Drug Alcohol Depend 209:107901
pubmed: 32126454
pmcid: 7219106
doi: 10.1016/j.drugalcdep.2020.107901
Diasso PDK, Abou-Kassem D, Nielsen SD, Main KM, Sjøgren P, Kurita GP (2023) Long-term opioid treatment and endocrine measures in chronic non-cancer pain patients. Eur J Pain 27(8):940–951
pubmed: 37243401
doi: 10.1002/ejp.2136
Hu JL, Zhang WJ (2023) The role and pharmacological properties of P2Y12 receptor in cancer and cancer pain. Biomed Pharmacother 157:113927
pubmed: 36462316
doi: 10.1016/j.biopha.2022.113927
Turk DC, Wilson HD, Cahana A (2011) Treatment of chronic noncancer pain. Lancet 377:2226–2235
pubmed: 21704872
doi: 10.1016/S0140-6736(11)60402-9
Huang S, Dong W, Lin X, Xu K, Li K, Xiong S, Wang Z, Nie X, Bian JS (2024) Disruption of the Na+/K+-ATPase-purinergic P2X7 receptor complex in microglia promotes stress-induced anxiety. Immunity 57(3):495-512.e11
pubmed: 38395698
doi: 10.1016/j.immuni.2024.01.018
Miras-Portugal MT, Sebastián-Serrano Á, de Diego GL, Díaz-Hernández M (2017) Neuronal P2X7 receptor: involvement in neuronal physiology and pathology. J Neurosci 37(30):7063–7072
pubmed: 28747389
pmcid: 6705729
doi: 10.1523/JNEUROSCI.3104-16.2017
Queipo MJ, Gil-Redondo JC, Morente V, Ortega F, Miras-Portugal MT, Delicado EG, Pérez-Sen R (2018) P2X7 Nucleotide and EGF receptors exert dual modulation of the dual-specificity phosphatase 6 (MKP-3) in granule neurons and astrocytes, contributing to negative feedback on ERK signaling. Front Mol Neurosci 10:448
pubmed: 29375309
pmcid: 5767727
doi: 10.3389/fnmol.2017.00448
Zhang J, Gao L, Zhang Y, Wang H, Sun S, Wu LA (2024) Involvement of microglial P2X7 receptor in pain modulation. CNS Neurosci Ther 30(1):e14496
pubmed: 37950524
doi: 10.1111/cns.14496
Yan J, Sun J, Zeng Z (2018) Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor. Inflammopharmacology 26(2):395–402
pubmed: 28825192
doi: 10.1007/s10787-017-0388-2
Wu P, Wang Y, Liu Y, Liu Y, Zhou G, Wu X, Wen Q (2023) Emerging roles of the P2X7 receptor in cancer pain. Purinergic Signal 19(2):441–450
pubmed: 36400869
doi: 10.1007/s11302-022-09902-1
Huang ZX, Lu ZJ, Ma WQ, Wu FX, Zhang YQ, Yu WF, Zhao ZQ (2014) Involvement of RVM-expressed P2X7 receptor in bone cancer pain: mechanism of descending facilitation. Pain 155(4):783–791
pubmed: 24447511
doi: 10.1016/j.pain.2014.01.011
Yuan X, Qian N, Ling S, Li Y, Sun W, Li J, Du R, Zhong G, Liu C, Yu G, Cao D, Liu Z, Wang Y, Qi Z, Yao Y, Wang F, Liu J, Hao S, Jin X, Zhao Y, Xue J, Zhao D, Gao X, Liang S, Li Y, Song J, Yu S, Li Y (2021) Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics 11(3):1429–1445
pubmed: 33391543
pmcid: 7738874
doi: 10.7150/thno.45351
Jin X, Cheng J, Zhang Q, Ji H, Zhu C, Yang Y, Zhou Y, Yu G, Wang C, Tang Z (2023) Aconitine - A promising candidate for treating cold and mechanical allodynia in cancer induced bone pain. Biomed Pharmacother 161:114284
pubmed: 36868017
doi: 10.1016/j.biopha.2023.114284
McNamara NB, Munro DAD, Bestard-Cuche N, Uyeda A, Bogie JFJ, Hoffmann A, Holloway RK, Molina-Gonzalez I, Askew KE, Mitchell S, Mungall W, Dodds M, Dittmayer C, Moss J, Rose J, Szymkowiak S, Amann L, McColl BW, Prinz M, Spires-Jones TL, Stenzel W, Horsburgh K, Hendriks JJA, Pridans C, Muramatsu R, Williams A, Priller J, Miron VE (2023) Microglia regulate central nervous system myelin growth and integrity. Nature 613(7942):120–129
pubmed: 36517604
doi: 10.1038/s41586-022-05534-y
Wu P, Zhou G, Wu X, Lv R, Yao J, Wen Q (2022) P2X7 receptor induces microglia polarization to the M1 phenotype in cancer-induced bone pain rat models. Mol Pain 18:17448069211060962
pubmed: 35057643
pmcid: 8961217
doi: 10.1177/17448069211060962
Zhang RX, Liu B, Wang L, Ren K, Qiao JT, Berman BM, Lao L (2005) Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 118(1–2):125–136
pubmed: 16154703
doi: 10.1016/j.pain.2005.08.001
Yang Y, Li H, Li TT, Luo H, Gu XY, Lü N, Ji RR, Zhang YQ (2015) Delayed activation of spinal microglia contributes to the maintenance of bone cancer pain in female Wistar rats via P2X7 receptor and IL-18. J Neurosci 35(20):7950–7963
pubmed: 25995479
doi: 10.1523/JNEUROSCI.5250-14.2015
Wang W, Zhong X, Li Y, Guo R, Du S, Wen L, Ying Y, Yang T, Wei XH (2019) Rostral ventromedial medulla-mediated descending facilitation following P2X7 receptor activation is involved in the development of chronic post-operative pain. J Neurochem 149(6):760–780
pubmed: 30570747
doi: 10.1111/jnc.14650
Hansen RR, Nielsen CK, Nasser A, Thomsen SIM, Eghorn LF, Pham Y, Schulenburg C, Syberg S, Ding M, Stojilkovic SS, Jorgensen NR, Heegaard AM (2011) P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain 152(8):1766–1776
pubmed: 21565445
pmcid: 6463294
doi: 10.1016/j.pain.2011.03.024
Falk S, Schwab SD, Frøsig-Jørgensen M, Clausen RP, Dickenson AH, Heegaard AM (2015) P2X7 receptor-mediated analgesia in cancer-induced bone pain. Neuroscience 291:93–105
pubmed: 25686524
doi: 10.1016/j.neuroscience.2015.02.011
Li P, Zhang Q, Xiao Z, Yu S, Yan Y, Qin Y (2018) Activation of the P2X7 receptor in midbrain periaqueductal gray participates in the analgesic effect of tramadol in bone cancer pain rats. Mol Pain 14:1744806918803039
pubmed: 30198382
pmcid: 6176534
doi: 10.1177/1744806918803039
Falk S, Appel CK, Bennedbæk HB, Al-Dihaissy T, Unger A, Dinkel K, Heegaard AM (2019) Chronic high dose P2X7 receptor inhibition exacerbates cancer-induced bone pain. Eur J Pharmacol 845:48–55
pubmed: 30582910
doi: 10.1016/j.ejphar.2018.12.032
Zhao X, Liu HZ, Zhang YQ (2016) Effect of P2X7 receptor knock-out on bone cancer pain in mice. Sheng Li Xue Bao 68(3):224–232
pubmed: 27350194
Demeules M, Scarpitta A, Abad C, Gondé H, Hardet R, Pinto-Espinoza C, Eichhoff AM, Schäfer W, Haag F, Koch-Nolte F, Adriouch S (2020) Evaluation of P2X7 receptor function in tumor contexts using rAAV vector and nanobodies (AAVnano). Front Oncol 10:1699
pubmed: 33042812
pmcid: 7518291
doi: 10.3389/fonc.2020.01699
Barberà-Cremades M, Gómez AI, Baroja-Mazo A, Martínez-Alarcón L, Martínez CM, de Torre-Minguela C, Pelegrín P (2017) P2X7 Receptor induces tumor necrosis factor-α converting enzyme activation and release to boost TNF-α production. Front Immunol 8:862
pubmed: 28791020
pmcid: 5523084
doi: 10.3389/fimmu.2017.00862
Hang RX, Liu B, Wang L, Ren K, Qiao JT, Berman BM, Lao L (2005) Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 118(1–2):125–136
Ying YL, Wei XH, Xu XB, She SZ, Zhou LJ, Lv J, Li D, Zheng B, Liu XG (2014) Over-expression of P2X7 receptors in spinal glial cells contributes to the development of chronic postsurgical pain induced by skin/muscle incision and retraction (SMIR) in rats. Exp Neurol 261:836–843
pubmed: 25242211
doi: 10.1016/j.expneurol.2014.09.007
Song J, Ying Y, Wang W, Liu X, Xu X, Wei X, Ruan X (2018) The role of P2X7R/ERK signaling in dorsal root ganglia satellite glial cells in the development of chronic postsurgical pain induced by skin/muscle incision and retraction (SMIR). Brain Behav Immun 69:180–189
pubmed: 29155323
doi: 10.1016/j.bbi.2017.11.011